Abstract: The pathogenesis of inflammatory bowel disease is likely to involve interaction between genetic factors, innate immunity, and the enteric microbiota. Alterations in the composition of the normal commensal microbiota may play a pathogenic role.
Abstract: Significant advances in cancer immunotherapy have been made in recent years and one such tool is the use of double-stranded RNA (dsRNA) which is the molecular pattern of virus infection
Abstract: Acute pancreatitis represents a set of dynamic and systematic and pathophysiological changes which are a result of autodigestive activation of pancreatic proenzyme
Abstract: Metallic or plastic stents are used for palliating inoperable malignant hilar obstruction. It is unclear if there is a difference between metallic versus plastic stenting in these patients.
Abstract: Condyloma acuminatum is caused by human papilloma virus, and occurs more often in homosexual males or immune suppressed patients.
Abstract: Although an extraperitoneal colostomy is often performed to prevent postoperative parastomal hernia formation after an open abdominoperineal resection for rectal neoplasm’s, it is not typically conducted via a laparoscopic approach because of the difficulty associated with the extraperitoneal route .
Abstract: Splenosis is the auto transplantation of splenic tissue generally seen after traumatic injury or elective splenectomy. Although this condition affects one to two thirds of patients submitted to splenectomy for trauma
Austin Journal of Gastroenterology is an open access, peer reviewed, scholarly journal dedicated to publish articles related to original and latest advancement of in the field of Gastroenterology.
The aim of this journal is to provide a platform for research scholars and academicians around the globe to promote, share, and discuss various new issues and developments in different fields of
Safety Profile of Anti-TNF Agents in Polish Pediatric Patients with Crohn’s Disease
Abstract In recent years, monoclonal antibodies against TNF-alpha, infliximab (IFX) and Adalimumab, have been gaining increasing popularity in Crohn’s disease (CD) management.